PHARPharming Group N.V.

Nasdaq pharming.com


$ 7.81 $ -0.23 (-2.81 %)    

Thursday, 27-Jun-2024 15:59:56 EDT
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 7.86
$ 7.81
$ 0.00 x 0
$ 0.00 x 0
$ 7.81 - $ 7.81
$ 6.97 - $ 16.71
4,173
na
5.27B
$ 0.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-pharming-maintains-37-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

 pharming-q1-2024-gaap-eps-002-misses-001-estimate-sales-55586m-miss-68425m-estimate

Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 2...

 reported-earlier-pharming-announces-completion-of-enrollment-in-pediatric-clinical-trial-of-leniolisib

Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the completion of patient enrollment ...

 hc-wainwright--co-reiterates-buy-on-pharming-maintains-37-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 pharming-group-expects-2024-total-revenue-of-280m-295m

Outlook/Summary For 2024, the Company anticipates: Total revenues between US$280 million and US$295 million (14% to 20% gro...

 pharming-q4-eps-000-up-from-002-yoy-sales-8120m-up-from-5462m-yoy

Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.00 per share. This is a 120 percent increase over losses of $(0.02) pe...

 whats-going-on-with-netherlands-based-biopharma-company-pharming-shares-today

Pharming Group (NASDAQ: PHAR) updated its full-year 2023 guidance, including RUCONEST and Joenja revenues, and a progress updat...

 pharming-group-updates-its-fy23-guidance-expects-revenue-to-increase-by-19-yoy-to-around-245m-with-ruconest-revenues-10-and-joenja-revenues-of-18m

Preliminary, unaudited cash and cash equivalents, together with restricted cash and marketable securities, are expected to to...

 pharming-group-expands-research-on-leniolisib-for-additional-primary-immunodeficiencies-targets-phase-2-trial-initiation-in-2q24

Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) ann...

 pharming-announces-first-patient-dosed-in-pediatric-clinical-trial-for-children-aged-1-to-6-years-for-leniolisib

Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)/(NASDAQ:PHAR) announces that the ...

 ibm-servicenow-lennox-morningstar-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking t...

 earnings-scheduled-for-october-26-2023

Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on re...